Building Better Biologics: Early Strategies For Optimizing The Progression Of Biotherapeutic Candidates To First In Human Studies And Beyond

Developing biologic drugs, especially complex ones, requires a strong foundation from the very beginning. A smart, integrated strategy for choosing candidates, conducting preclinical evaluations, and preparing for manufacturing is crucial for both clinical and commercial success.

This webinar shows how using the right technologies and strategies early on can help you optimize candidate selection, streamline progression to cell line development, boost manufacturability, and reduce future risks.

We delve into how advanced technologies like in silico prediction for immunosafety, immunogenicity, and manufacturability, along with high-yield, scalable platforms such as the GS Gene Expression System®, can significantly improve your chances of biomanufacturing success for various advanced molecules.

We also discuss common pitfalls and provide actionable strategies to quickly move your biologic candidates from late discovery to first-in-human studies. Discover how these approaches can lead to higher success rates, smarter resource investment, and a smoother path to IND submissions and commercialization.